



Crescendo Biologics to attend 36th Annual J.P. Morgan Healthcare Conference 2018, San Francisco

Cambridge, UK, 2 January 2018 – Crescendo Biologics Limited (Crescendo), the drug developer of novel, targeted T-cell engaging therapeutics, announces that members of the senior management team will be in San Francisco from 8-11 January for the 36th Annual J.P. Morgan Healthcare Conference.

Attendees from the Company will include Peter Pack, CEO, Theo Harold, CFO, Phil Bland-Ward, CSO and Tad Stewart, CBO.

To arrange a meeting with the team, please contact info@crescendobiologics.com.

Ends

For more information, please contact:

Crescendo Biologics Dr Peter Pack, CEO	Tel:44 (0)1223 497140 info@crescendobiologics.com
Instinctif Partners Dr Christelle Kerouedan / Melanie Toyne-Sewell	Tel:44 (0)20 7457 2020 crescendo@instinctif.com

Notes to Editors:

About Crescendo Biologics Ltd

Crescendo Biologics is a biopharmaceutical company developing potent, highly differentiated multi-functional Humabody[®] therapeutics in oncology, with an internal focus on biologics for Targeted T-cell Therapy with novel modes-of-action. It is pursuing novel Humabody[®]-based product opportunities, through in-house development and strategic partnerships, in both multi-functional immuno-oncology modulators and Humabody[®] Drug Conjugates (HDCs), the next generation of ADCs.

The Company's Humabody[®] therapeutics are based on its unique, patent protected, transgenic mouse platform, generating 100% human V_H domain building blocks (Humabody[®] V_H) comprising the full structural diversity of the human V_H repertoire and superior biophysical properties as a result of their in vivo maturation.

Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Touchstone Innovations (formerly known as Imperial Innovations), Takeda and Astellas.

For more information, please visit the website: www.crescendobiologics.com